Drugs / MNC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01167751 | Jan 2008 → Jun 2012 | myocardial infarction | Royan Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01167751 ↗ |
| Known as | MNCs | “The regenerative potential of bone marrow-derived mononuclear cells (MNCs) and CD133+ stem cells in the heart varies in terms of their pro-angiogenic effects.” PMID 29633605 ↗ Mar 2018 |